Evotec SE (EVO) stock

EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 8, 2026Score 4/30

$1.66−0.03 (-1.78%)

Close on Nov 12, 2026Market cap $590.23MP/E –Yield –

Evotec ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was €43.26M. The highest annual figure on record is €111.40M in fiscal 2021.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	€43.26M	–
FY2024	Dec 31, 2024	-€40.90M	-190.0%
FY2023	Dec 31, 2023	€45.47M	-56.3%
FY2022	Dec 31, 2022	€104.05M	-6.6%
FY2021	Dec 31, 2021	€111.40M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVO.

Revenue growth-1.1% · median 15.8%

Operating margin-7.1% · median -64.0%

Advertisement
300 × 250

See a number that looks wrong?